BRIEF—STADA Arz acquires more brands from Sanofi

German drugmaker STADA Arzneimittel is significantly expanding its European Consumer Healthcare portfolio by acquiring another range of well-established and leading local and regional consumer healthcare brands from French pharma major Sanofi in European countries, including Belgium, Germany, Hungary, Spain and the UK , as well as Nordic countries.

The transaction covers several brands, including: Antistax for pain relief and tiredness in legs; the allergy eye drops Lomudal; Omnivit vitamins; and Opticrom allergy eye drops. In addition, the two painkillers AAS and Dolalgial, as well as Bila-Git for gallbladder complaints, are part of the acquired portfolio.

Financial terms of the transaction were not disclosed.

This acquisition of more consumer brands from Sanofi is the latest example of the implementation of an ongoing successful business-development strategy, STADA noted.

This was preceded by a transaction for 16 brands from Sanofi in 2021, as well as an agreement with Sanofi about the distribution of Sanofi's consumer healthcare portfolio in 10 countries in Central Asia in 2022.